A Study to Learn About a Combined COVID-19 and Influenza Shot in Healthy Adults

Inclusion Criteria:

• Male or female participants aged 50 years or older at Visit 1 (Day 1).

• Participants who are willing and able to comply with all scheduled visits, theinvestigational plan, laboratory tests, lifestyle considerations, and other studyprocedures.

• Healthy participants who are determined by medical history, physical examination (ifrequired), and clinical judgment of the investigator to be eligible for inclusion inthe study.

• Capable of giving signed informed consent as described in the protocol, whichincludes compliance with the requirements and restrictions listed in the informedconsent document (ICD) and in the protocol.

Exclusion Criteria:

• Any medical or psychiatric condition including recent (within the past year) oractive suicidal ideation/behavior or laboratory abnormality that may increase therisk of study participation or, in the investigator's judgment, make the participantinappropriate for the study.

• Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), orhepatitis B virus (HBV).

• History of severe adverse reaction associated with any vaccine and/or severeallergic reaction (eg, anaphylaxis) to any component of the study interventions.

• Participants with a history of autoimmune disease or an active autoimmune diseaserequiring therapeutic intervention, including but not limited to systemic orcutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, multiplesclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura,glomerulonephritis, autoimmune thyroiditis, temporal arteritis, psoriasis, and/orinsulin-dependent diabetes mellitus.

• Immunocompromised individuals with known or suspected immunodeficiency, determinedby history and/or laboratory/physical examination.

• Current heart disease, uncontrolled hypertension, or a prior history of myocarditisor pericarditis.

• Bleeding diathesis or condition associated with prolonged bleeding that would, inthe opinion of the investigator, contraindicate intramuscular injection.

• Women who are pregnant, plan to become pregnant during the study, or arebreastfeeding.

• Prior history of ischemic stroke or transient ischemic attack.

• Prior history of Guillain-Barré syndrome (GBS).

• Participants with a calculated BMI of ≥35.

• Receipt of chronic medications with known systemic immunosuppressant effects (including cytotoxic agents or systemic corticosteroids), or radiotherapy, within 60days before enrollment through conclusion of the study.

• Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used forthe treatment or prevention of COVID 19 or those that are consideredimmunosuppressive, from 90 days before study intervention administration, or plannedreceipt throughout the study.

• Vaccination with any investigational or licensed influenza vaccine within 6 months (180 days) before study intervention administration, or ongoing receipt of chronicantiviral therapy with activity against influenza.

• Vaccination with any investigational or licensed COVID-19 vaccine within 6 months (180 days) before study intervention administration.

• Participation in other studies involving administration of an investigationalproduct within 28 days prior to, and/or during, participation in this study.

• Investigator site staff directly involved in the conduct of the study and theirfamily members, site staff otherwise supervised by the investigator, and sponsor andsponsor delegate employees directly involved in the conduct of the study and theirfamily members.

• Deprived of freedom by an administrative or court order, or in an emergency setting,or hospitalized involuntarily.

• Current alcohol abuse or drug addiction that in the opinion of the investigatormight interfere with the study conduct or completion.